Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.

Operator: Thank you for standing by, and welcome to the Lightbridge Corporation business update and fiscal year 2025 ...

Vibativ, Sancuso, and new Talicia brand led revenue gains, with initial Talicia sales commencing in Q4. Balance Sheet ...

Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported ...